ScholarX: LIM, HO YEONG

Detailed Information

LIM, HO YEONG (임호영)

Medicine (Medicine)

Research Area

Tel 02-3410-0914
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Gastric cancer:21||Hepatocellular carcinoma:20||hepatocellular carcinoma:16||Sorafenib:14||Chemotherapy:13||Colorectal cancer:12||gastric cancer:11||Oxaliplatin:9||2:8||Gemcitabine:8||Prognosis:7||chemotherapy:7||3:7||immunotherapy:7||Capecitabine:7||S1:6||Simvastatin:6||Bevacizumab:6||6:6||cisplatin:6||Renal cell carcinoma:6||capecitabine:5||Regorafenib:5||biomarker:5||Pazopanib:5||sorafenib:5||28:4||Pancreatic cancer:4||Atezolizumab plus bevacizumab:4||regorafenib:4||283424425:4||4:4||Stomach neoplasms:4||Carcinoma:4||Advanced gastric cancer:4||radiotherapy:4||biliary tract cancer:4||Lenvatinib:4||HCC:4||Biliary tract cancer:4||Docetaxel:4||Pembrolizumab:4||prognosis:4||Ramucirumab:4||Radiotherapy:4||Cisplatin:4||Advanced HCC:3||Cancer:3||Atezolizumab:3||hepatocellular:3||Colorectal neoplasms:3||Advanced hepatocellular carcinoma:3||Irinotecan:3||KRAS:3||nextgeneration sequencing:3||advanced hepatocellular carcinoma:3||overall survival:3||oxaliplatin:3||paclitaxel:3||Biomarker:3||bevacizumab:3||1:3||Guidelines:3||ERCC1:3||colorectal cancer:3||242:3||survival:3||Stomach neoplasm:3||Management:3||Phase 1:3||Everolimus:3||pancreatic cancer:2||alphafetoprotein:2||nivolumab:2||PDL1:2||advanced gastric cancer:2||MerTK:2||chemoradiation:2||Carcinoma, hepatocellular:2||Metabolic tumor volume:2||KRAS mutation:2||Preoperative chemoradiotherapy:2||Gefitinib:2||Nivolumab:2||PIK3CA mutation:2||Gastroenteropancreatic neuroendocrine tumor (GEPNET):2||HER2:2||refractory cancer:2||Intraperitoneal administration:2||Cetuximab:2||Aflibercept:2||FOLFOX:2||Chemoradiation:2||safety:2||colorectal carcinoma:2||Gallbladder neoplasms:2||Palliative chemotherapy:2||Combination therapy:2||Combination chemotherapy:2||liver cancer:2||NASH:2||small cell lung cancer:2||Immunohistochemistry:2||lenvatinib:2||TACE:2||MMR:2||Patientderived cell:2||Predictive marker:2||MSI:2||irinotecan:2||Prognostic factors:2||Cabozantinib:2||Prognostic factor:2||gemcitabine:2||immunohistochemistry:2||Trastuzumab:2||Colorectal cancer (CRC):2||best supportive care:2||Erlotinib:2||PD1 blockade:2||pembrolizumab:2||Rectal cancer:2||atezolizumab plus bevacizumab:2||182:2||Rectal neoplasms:2||cMET:2||Recurrence:2||6131352443829325:2||HRD:1||Haptoglobin:1||Healthrelated quality of life:1||Hedgehog pathway:1||Hematogenous:1||Hemodialysis:1||Hepatitis B virus:1||Hepatocellular:1||Hepatocellular carcinoma (HCC):1||Hepatocellular carcinoma (hcc) cells:1||Hepatocellular carcinoma, nonresectable:1||Hepatocellular carcinomas (HCC):1||Hepatocyte growth factor:1||Heptaplatin:1||Histology:1||Hyperglycemia:1||Hyperprogressive disease:1||Ifosfamide:1||Immune checkpoint inhibitor:1||Immune checkpoint inhibitors:1||Immunohistochemical stain:1||Immunotherapy:1||Indirect treatment comparison (ITC):1||Induced hyperthermia:1||Inflammation:1||Initial dose:1||Intensive care unit:1||Intrathecal chemotherapy:1||Kras:1||KEYNOTE394:1||KLB:1||KML001:1||Ki67 proliferation index:1||Ki67 index:1||Kidney:1||Korea:1||LAG3:1||LMP1:1||Lateral lymph node:1||Lateral pelvic recurrence:1||Leptomeningeal:1||Lifesustaining treatments:1||Liver cancer:1||Longterm followup:1||Lung metastasis:1||MAP2K1 mutation:1||MEK inhibitor:1||MET:1||MET alterations:1||MET amplification:1||MET exon 14 skipping:1||MET kinase inhibitors:1||MET monoclonal antibodies:1||Magnetic resonance imaging:1||Matchingadjusted indirect comparison (MAIC):1||Maximum tolerated dose:1||Metastasis:1||Metastatic cancer:1||Metastatic colorectal cancer:1||Metatstatic colorectal cancer:1||Methylation array:1||Molecular profiling:1||Molecular screening:1||Monocarboxylate transporter:1||Monoclonal antibody:1||Monoclonal antibody (mAb):1||Multidrug Resistance:1||Multidisciplinary approach:1||Nglycan:1||NAFLD:1||NGS:1||NONMEM:1||NTRK1 rearrangement:1||Neoadjuvant:1||Neoadjuvant chemoradiotherapy:1||Neoplasm staging:1||Neurotoxicity:1||Neutrophiltolymphocyte ratio:1||Next generation sequencing:1||Nextgeneration sequencing:1||Nextgeneration sequencing (NGS):1||Nonclear cell renal cell carcinoma:1||Nontransitional cell carcinoma:1||Nutrition:1||OPB111077:1||Objective response:1||Oblique angle:1||Observational study:1||Offlabel use:1||Ovarian metastasis:1||Ovarian metastatectomy:1||PD1:1||PD1 inhibitor:1||PDL1 inhibitor:1||PI3K/Akt pathway:1||PIK3CA:1||PIK3CA amplification/mutation:1||PIK3CAE542K:1||PRO007:1||PTEN loss:1||Paclitaxel:1||Pain:1||Palliative treatment:1||PanAsian:1||Pancreatic neuroendocrine tumor:1||Pathologic complete response:1||Pathology:1||Patientderived cells:1||Patientreported outcomes:1||Patterns of failure:1||Pemetrexed:1||Perifosine:1||Peritoneal seeding:1||Pharmacogenomics:1||Pharmacokinetics:1||Phase I:1||Phase I study:1||Phase II clinical trial:1||Phase II study:1||Plasma biomarkers:1||Postoperative chemoradiotherapy:1||Prediabetes:1||Predictive:1||Preoperative:1||Previously treated patients:1||Prognostic:1||Prognostic marker:1||Prognostic model:1||Programmed cell death ligand 1 expression:1||Programmed cell death protein 1:1||Programmed death 1:1||Programmed death ligand 1 expression:1||Programmed deathligand 1 (PDL1):1||Prospective:1||Pulmonary metastasis:1||Pulmonary toxicity:1||Quality of life:1||RAD001:1||RAF inhibitor:1||RAS signature:1||RICTOR:1||RNF11:1||RT:1||RWD:1||Radi:1||Radiation recall dermatitis:1||Radiation therapy:1||Randomized controlled trial:1||Randomized trial:1||Rapid infusion:1||Ras/Raf/MAPK pathway:1||Real Word:1||Realworld evidence:1||Receptor kinase inhibiti:1||Refractory gastric cancer:1||Resminostat:1||Response:1||Response evaluation criteria in solid tumours:1||Retrospective study:1||Ribonucleic acid sequencing:1||Risk factors:1||SAIT301:1||SMO:1||STAT3 transcription factor:1||Safety:1||Salvage therapy:1||Sarcopenia:1||Second line chemotherapy:1||Secondline therapy:1||Sidedness:1||Skin entry distance:1||Solid tumors:1||Somatic:1||Somatic mutation:1||Sor:1||Stomach cancer:1||Sunitinib:1||Sunitinib, dose, toxicity, response:1||Surrogate endpoint:1||Survey:1||Survival:1||Survival benefit:1||Synthetic 3hydroxy3methyglutaryl coenzyme A (HMGCoA):1||Systemic chemotherapy:1||TAS102:1||TAS102 plus bevacizumab:1||TGFβ:1||TMB:1||TPK1:1||TRKA immunohistochemistry:1||Tanibirumab:1||Target:1||Targeted therapy:1||Terminal cancer care:1||The effect of bevacizumab was not different between LC and RC and between MSS and the MSIH tumors:1||Therapy:1||Tigatuzumab:1||Total lesion glycolysis:1||Treatment:1||TruSight™ Oncology 500 assay:1||Tumor:1||Tumour growth dynamics:1||Tyrosine kinase inhibitor:1||Tyrosine kinase inhibitor (TKI):1||Tyrosine kinase inhibitors:1||Unmet need:1||Urachal cancer:1||Urinary bladder:1||Urothelial cancer:1||Urothelial carcinoma:1||VEGFR2 inhibitor:1||Vascular endothelial growth factor (VEGF):1||Vismodegib:1||WHO classification:1||Wholeexome sequencing:1||Workforce performance:1||XELIRI/FOLFIRI chemotherapy:1||XELOX:1||adjuvant:1||adjuvant chemotherapy:1||adjuvant therapy:1||advanced gastric cancer (AGC):1||anaplastic lymphoma kinase (ALK) rearrangement:1||and oxaliplatin (FOLFOX):1||antiangiogenic therapy:1||antineoplastic agents:1||arginine:1||arsenical:1||atezolizumab:1||axitinib:1||bifunctional fusion protein:1||biliary complication:1||breast cancer:1||cerbB2 gene:1||cabozantinib:1||cancer:1||cell free DNA (cfDNA):1||cellfree DNA (cfDNA):1||checkpoint inhibitor:1||chemotherapy, end of life:1||cholangiocarcinoma:1||circumferential extent:1||claudin 18.2:1||clinical practice patterns:1||clinical trials:1||clinicopathologic factors:1||colon cancer:1||colorectal cancer (CRC):1||combination therapy:1||combination treatment:1||consensus:1||cord blood:1||crizotinib:1||cryopreserved:1||dRecurrence:1||diffuse large B cell lymphoma:1||digital sequencing:1||docetaxe:1||docetaxel:1||droplet digital PCR (ddPCR):1||efficacy:1||endothelial cells:1||eosinophils:1||epidermal growth factor receptor:1||etiology:1||etoposide:1||everolimus:1||extensive:1||firstline systemic treatment:1||fluorouracil:1||gall bladder cancer:1||gastroenteropancreatic neuroendocrine carcinoma (GEPNEC)s:1||gastrointestinal cancer:1||gastrointestinal malignancies:1||genomewide association:1||genomic test:1||genomics:1||growth factor receptor antagonists:1||handfoot syn:1||hemophagocytic syndrome:1||hepatocyte growth factor:1||highthroughput drug screening:1||human epidermal growth factor receptor 2 (HER2):1||ifosfamide:1||immune check point inhibitor:1||immune checkpoint inhibitor:1||immune checkpoint inhibitors:1||intestinal lymphoma:1||intrinsic resistance:1||ipilimumab:1||lesionlevel response:1||leucovorin:1||liquid biopsy:1||liver neoplasms:1||local control:1||lymph nodes:1||lymphomaassociated hemophagocytic syndrome:1||mTOR inhibitor:1||mTORC1/2:1||metastatic colorectal cancer:1||mismatch repair deficiency (dMMR):1||molecular profiling:1||monotherapy:1||multicenter:1||mutation:1||natural history:1||neoadjuvant chemotherapy:1||neuropathy:1||neutrophiltolymphocyte ratio:1||next generation sequencing:1||nextgeneration sequencing (NGS):1||nonclear cell:1||oncogene:1||outcome:1||overall survival analysis:1||pSTAT3:1||pancreatic adenocarc:1||pancreatic adenocarcinoma:1||pathologic differentiation:1||pathway:1||patient&:1||patientderived cells:1||patientderived tumor cell:1||patientderived tumor cells:1||pazopanib:1||pegylated arginine deiminase (ADIPEG 20):1||pemetrexed:1||perihilar region:1||peritoneal mesothelioma:1||pharmacodynamics:1||pharmacokinetics:1||phase 2:1||phase I:1||platinum:1||preoperative chemoradiotherapy:1||primary tumor site:1||prognosic factor:1||prognostic:1||prognostic factors:1||programmed cell death 1 ligand 1:1||programmed cell deathligand 1 (PDL1):1||programmed deathligand 1 (PDL1):1||proton beam therapy:1||quality of life:1||rectal cancer:1||recurrence:1||recursive partitioning analysis:1||renal cell carc:1||renal cell carcinoma:1||reported outcome measures:1||response rate:1||salvage regimen:1||salvage therapy:1||salvage treatment:1||secondline chemotherapy:1||secondline treatment / 2L treatment:1||simvastatin:1||sirolimus:1||solid cancer:1||stage smallcell lung cancer:1||sunitinib:1||surgery:1||survival benefit:1||target therapy:1||targeted agents:1||telomere:1||threeweek schedule:1||time to progression:1||transitional cell carcinoma:1||trastuzumab:1||tumor heterogeneity:1||tumor marker:1||tumor mutational burden:1||tumor purity:1||twodrug combination:1||tyrosine kinase inhibitor:1||urothelial carcinoma:1||urothelium:1||viral:1||vitamin:1||young:1||#8208:1||zolbetuximab:1||14:1||18FFDG PET/CT . Pancreatic neuroendocrine tumor . Metabolic tumor volume . Total lesion glycolysis . Prognosis:1||2614921992823:1||2614922769:1||2615669263:1||29814522218410229124:1||30min infusion:1||32822709760:1||3282330146863534:1||3604:1||3809227449:1||3809233551:1||5:1||61322525756274:1||613326736506749:1||61361564625486283:1||6136156463281:1||ABE index:1||ADIPEG20:1||AFP:1||ASS1:1||ATM:1||AZD2014:1||Acute kidney injury:1||Adenocarcinoma:1||Adenocarcinoma of ampulla of Vater:1||Adjuvant:1||Adjuvant CCRT:1||Adjuvant chemotherapy:1||Adjuvant therapy:1||Advanced BCLC:1||Advanced gastric cancer (AGC):1||Advanced pancreatic cancer:1||Advanced soft tissue sarcoma:1||Adverse effect:1||Alphafetoprotein (AFP):1||Ampliseq:1||Antiangiogenic agent:1||Anticancer:1||Argininosuccinate synthetase:1||Asia:1||Asian patients:1||Awareness and willi:1||Barcelona clinic liver cancer stage:1||Bax:1||Biliary tract cancers:1||Biliary tract neoplasms:1||Biomarkers:1||Biweekly:1||Bone marrow:1||Brivanib, mRECIST:1||CA199:1||CAPOX:1||CDK4/6 inhibitor:1||CPT11:1||CS1008:1||Cancer clinical trial:1||Cancer immunotherapy:1||Capecitab:1||Carboplatin:1||Carcinoembryonic antigen:1||Carcinomatosis:1||Cardiopulmonary resuscitation:1||Caregivers:1||Castrateresistant prostate cancer:1||Cellfree DNA (cfDNA):1||Cerebrospinal fluid (CSF):1||Checkpoint inhibitor:1||ChildPugh B:1||Cholangiocarcinoma:1||Chronic pancreatitis:1||Circulating tumor cell:1||Circulating tumor cells (CTCs):1||Cisplatinbased combination chemotherapy:1||Cisplatinunfit:1||Clearcell carcinoma:1||Clinical trials:1||Coeliac plexus block:1||Colonic neoplasms:1||Colorectal cancers:1||Concurrent chemoradiotherapy:1||DNA:1||DP:1||Diagnosis:1||Digital sequencing:1||Diseasefree survival:1||Dose limiting toxicity:1||Doxorubicin:1||Drug therapy:1||Drugassociated interstitial lung disease:1||ERBB2:1||ESMO guidelines:1||Egr1:1||Ekb569:1||Elderly:1||End of life:1||Epidermal Growth Factor Receptor (EGFR)Tyrosine Kinase Inhibitors (tkis):1||Epirubicin:1||EpsteinBarr virus:1||ErbB2 receptor:1||Ethnic groups:1||Extrahepatic spread:1||FGF19:1||FGFR2:1||FGFR2amplified:1||FGFR4:1||FLT3 amplification:1||FOLFIRI:1||Firstline:1||Firstline chemotherapy:1||Firstline therapy:1||Fluoropyrimidine:1||Fluorouracil (FU):1||GEMOX:1||GEPNEC:1||Gastric adenocarcinoma:1||Gastroenteropancreatic neuroendocrine carcinoma:1||Gemcitabine failure:1||Genome:1||Genomic analysis:1||Genomic test:1||Germ cell tumor:1||Glycolysis:1||Glycoprotein:1||Guardant360:1||HDAC:1||HER2 expression:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE